NEW YORK – Startup Scope Fluidics will soon launch a SARS-CoV-2 test on its fully integrated, fully automated rapid point-of-care molecular diagnostic instrument.
The Warsaw, Poland-based firm expects to submit the test along with its PCR One instrument to the US Food and Drug Administration by the end of the year and will follow shortly with a multiplex respiratory viral panel that includes COVID-19, influenza, and respiratory syncytial virus targets.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
